Clinical trialNCT04401293CompletedPhase 3Interventional

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

SponsorNorthwell HealthEnrollment257COVIDSars-CoV2

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than prophylaxis with institutional standard of care with prophylactic to intermediate-doses of UFH or LMWH

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Alex C Spyropoulos, MD
Northwell Health
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Beth Israel Newark
Newark, New Jersey, United States
Southside Hospital
Bay Shore, New York, United States
Huntington Hospital
Huntington, New York, United States
Lenox Hill Hospital
New York, New York, United States
Long Island Jewish Medical Center
Queens, New York, United States
Staten Island University Hospital
Staten Island, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Enoxaparin →Prophylactic/Intermediate Dose Enoxaparin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Apr 2020
Primary completion: 14 May 2021
Completion: 14 May 2021
Last update posted: 22 Nov 2021
Registered enrollment: 257
Registry id: NCT04401293

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.